由于大部分肝硬化患者易发生腹水,其中低钠血症往往伴随病程,而通过传统的限盐和利尿剂处理常反应不佳或因使用利尿剂产生不良反应,治疗困难。目前全新排水剂托伐普坦已应用于该类疾病的临床治疗,并取得了一定的进展,本文就此阐述,以便更好地了解托伐普坦对疾病的临床价值。肝硬化腹水伴低钠血症的形成及危害肝硬化失代偿期患者多伴有腹水的形成,流行病学调查显示,肝硬化腹水患者并发低钠血症(血清钠<135 mmol/L)的比例为50%~60%,且低血钠 As most patients with cirrhosis are prone to develop ascites, hyponatremia is often accompanied by the course of the disease, and treatment is often difficult due to poor response to conventional salt-limiting and diuretic treatments or adverse reactions due to diuretics. At present, the new drainage agent of tolvaptan has been used in the clinical treatment of such diseases and made some progress, this article elaborated in order to better understand the clinical value of tolvaptan on the disease. Cirrhosis with ascites with hyponatremia and the formation of cirrhosis and decompensated patients often associated with ascites, epidemiological survey showed that patients with cirrhosis and ascites hyponatremia (serum sodium <135 mmol / L) The proportion of 50% to 60%, and hyponatremia